Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Lucy A Culliford; Barnaby C Reeves; on behalf of the IVAN study investigators

doi:10.1016/S0140-6736(13)61501-9

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Usha Chakravarthy
, Simon P Harding
, Chris A Rogers
, Susan M Downes
, Andrew J Lotery
, Lucy A Culliford
, Barnaby C Reeves
, on behalf of the IVAN study investigators

Research output: Contribution to journal › Article (Academic Journal) › peer-review

682 Citations (Scopus)

Abstract

Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint.

Original language	English
Pages (from-to)	1258-1267
Journal	Lancet
Volume	382
Issue number	9900
Early online date	19 Jul 2013
DOIs	https://doi.org/10.1016/S0140-6736(13)61501-9
Publication status	Published - 12 Oct 2013

Bibliographical note

Research Groups and Themes

BTC (Bristol Trials Centre)
Centre for Surgical Research

Access to Document

10.1016/S0140-6736(13)61501-9

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61501-9/fulltext

Handle.net

Persistent link

Cite this

Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., Reeves, B. C., & on behalf of the IVAN study investigators (2013). Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet, 382(9900), 1258-1267. https://doi.org/10.1016/S0140-6736(13)61501-9

@article{787d6f4e083b495fb501c79b7461743e,

title = "Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial",

abstract = "Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint.",

author = "Usha Chakravarthy and Harding, \{Simon P\} and Rogers, \{Chris A\} and Downes, \{Susan M\} and Lotery, \{Andrew J\} and Culliford, \{Lucy A\} and Reeves, \{Barnaby C\} and \{on behalf of the IVAN study investigators\} and Maishman, \{Rachel L\}",

year = "2013",

month = oct,

day = "12",

doi = "10.1016/S0140-6736(13)61501-9",

language = "English",

volume = "382",

pages = "1258--1267",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "9900",

}

Chakravarthy, U, Harding, SP, Rogers, CA, Downes, SM, Lotery, AJ, Culliford, LA , Reeves, BC & on behalf of the IVAN study investigators 2013, 'Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial', Lancet, vol. 382, no. 9900, pp. 1258-1267. https://doi.org/10.1016/S0140-6736(13)61501-9

TY - JOUR

T1 - Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

AU - Chakravarthy, Usha

AU - Harding, Simon P

AU - Rogers, Chris A

AU - Downes, Susan M

AU - Lotery, Andrew J

AU - Culliford, Lucy A

AU - Reeves, Barnaby C

AU - on behalf of the IVAN study investigators

AU - Maishman, Rachel L

PY - 2013/10/12

Y1 - 2013/10/12

N2 - Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint.

AB - Bevacizumab has been suggested to have similar effectiveness to ranibizumab for treatment of neovascular age-related macular degeneration. The Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial was designed to compare these drugs and different regimens. Here, we report the findings at the prespecified 2-year timepoint.

UR - https://www.scopus.com/pages/publications/84880182117

U2 - 10.1016/S0140-6736(13)61501-9

DO - 10.1016/S0140-6736(13)61501-9

M3 - Article (Academic Journal)

C2 - 23870813

SN - 0140-6736

VL - 382

SP - 1258

EP - 1267

JO - Lancet

JF - Lancet

IS - 9900

ER -

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

Abstract

Bibliographical note

Research Groups and Themes

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this